Kommentar zu „SGLT2-Inhibitoren und Nierenfunktion“

• Literatur

• 1 Heerspink HJL, Stefansson BV, Correa-Rotter R. et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2020; 383: 1436-1446
• 2 Solomon SD, McMurray JJV, Claggett B. et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med 2022; 387: 1089-1098
• 3 The E-KCG, Herrington WG, Staplin N. et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 2023; 388: 117-127
• 4 Anders HJ, Davis JM, Thurau K. Nephron Protection in Diabetic Kidney Disease. N Engl J Med 2016; 375: 2096-2098